A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Clinical trial NCT05119933 · UNKNOWN

Trial details

NCT number: NCT05119933
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2021-11-09
Primary completion: 2023-06-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.